Pancreatic Cancer Research

ResearcherNational Cheng Kung UniversityActive in the last 2 years

Po-Hsien Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2997-5181; OpenAlex author ID A5101578024. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Macrophage activation determines muscle wasting in pancreatic cancer. First author DOI 10.1038/s41388-025-03434-9↗
  2. RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer. Last author DOI 10.1038/s41388-022-02325-7↗
  3. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer. Last author DOI 10.1186/s13148-020-00878-6↗
  4. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Co-author DOI 10.7150/thno.36830↗
  5. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer. First author DOI 10.1016/j.phrs.2017.01.006↗
  6. TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1. Co-author DOI 10.1038/onc.2016.378↗
  7. Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells. Co-author DOI 10.1038/oncsis.2017.61↗
  8. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Last author DOI 10.1016/j.neo.2016.10.003↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ya‐Chin Hou · 4 shared papers, 2019–2025 · strength 0.51
  2. Yan‐Shen Shan · 4 shared papers, 2019–2025 · strength 0.51
  3. Li-Yun Ding · 4 shared papers, 2016–2025 · strength 0.49
  4. Szu-Ying Chen · 2 shared papers, 2022–2025 · strength 0.33
  5. Chih‐Han Chang · 2 shared papers, 2022–2025 · strength 0.33
  6. Yi‐Ching Wang · 2 shared papers, 2020–2025 · strength 0.29
  7. Pei-Chia Su · 1 shared paper, 2025 · strength 0.20
  8. Hao‐Chen Wang · 2 shared papers, 2019–2020 · strength 0.18
  9. Ching‐Shih Chen · 2 shared papers, 2016–2017 · strength 0.17
  10. P-C Chu · 2 shared papers, 2017 · strength 0.14
  11. C. S. Chen · 2 shared papers, 2017 · strength 0.14
  12. Hsiao-Ching Chuang · 1 shared paper, 2017 · strength 0.10
  13. Ying‐Jui Chao · 1 shared paper, 2019 · strength 0.09
  14. Li‐Tzong Chen · 1 shared paper, 2019 · strength 0.09
  15. Tai‐Jan Chiu · 1 shared paper, 2019 · strength 0.09
  16. H-L Huang · 1 shared paper, 2017 · strength 0.07
  17. Sally E. Henderson · 1 shared paper, 2016 · strength 0.07
  18. Tanios Bekaii‐Saab · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.